Current Progress in Perioperative Chemotherapy for Biliary Tract Cancer

Overview

Journal Ann Gastroenterol Surg

Date 2023 Jul 7

PMID 37416744

Authors

Tatsuya Ioka

Yoshitaro Shindo

Makoto Ueno

Hiroaki Nagano

Affiliations

Soon will be listed here.

Abstract

Biliary tract cancer (BTCs) is a heterogeneous malignancy divided into cholangiocarcinoma, gallbladder cancer, and ampullary cancer. Due to little or no symptoms, most patients with BTCs are diagnosed with unresectable or metastatic disease. Only 20%-30% of all BTCs are suitable for potentially resectable diseases. Although radical resection with a negative surgical margin is the only potentially curative method for BTCs, most patients develop postoperative recurrence, which is associated with poor prognosis. Therefore, perioperative treatment is necessary to improve survival. There are very few randomized phase III clinical trials of perioperative chemotherapy due to the relative rarity of BTCs. Adjuvant chemotherapy with S-1 for patients with resected BTC significantly increased overall survival compared with upfront surgery in a recent ASCOT trial. In East Asia, S-1 is currently considered the standard adjuvant chemotherapy, while capecitabine may still be used in other areas. Since then, our phase III trial (KHBO1401), gemcitabine and cisplatin plus S-1 (GCS) has become the standard chemotherapy for advanced BTCs. GCS not only improved overall survival but demonstrated a high response rate. The efficacy of GCS as a preoperative neoadjuvant chemotherapy for resectable BTCs has been investigated in a randomized phase III trial (JCOG1920) in Japan. In this review, we summarize the current and ongoing clinical trials focusing on adjuvant and neoadjuvant chemotherapy for BTCs.

Citing Articles

[Frozen sections in hepatobiliary surgery].

Lang S, Heij L, Bednarsch J, Neumann U Chirurgie (Heidelb). 2025; .

PMID: 40085225 DOI: 10.1007/s00104-025-02264-5.

ASO Author Reflections: The Impact of Time to Surgery for Survival Outcome in Patients with Perihilar Cholangiocarcinoma.

Tohmatsu Y, Ohgi K, Ashida R, Yamada M, Otsuka S, Kato Y Ann Surg Oncol. 2025; 32(3):1835-1836.

PMID: 39751978 DOI: 10.1245/s10434-024-16758-9.

Time to Surgery Does Not Affect the Survival Outcome in Patients with Perihilar Cholangiocarcinoma.

Tohmatsu Y, Ohgi K, Ashida R, Yamada M, Otsuka S, Kato Y Ann Surg Oncol. 2024; 32(3):1808-1816.

PMID: 39633168 DOI: 10.1245/s10434-024-16628-4.

ASO Author Reflections: Ampulla of Vater Carcinoma with Advanced Pancreatic Invasion Imply Advanced Tumor Progression to Systemic Disease.

Miura Y, Ohgi K, Ohike N, Ashida R, Yamada M, Otsuka S Ann Surg Oncol. 2024; 31(13):9221-9222.

PMID: 39138775 DOI: 10.1245/s10434-024-16048-4.

The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials.

Vitale E, Rizzo A, Maistrello L, Nardulli P, Talienti T, Quaresmini D Front Oncol. 2024; 14:1409132.

PMID: 39091909 PMC: 11291215. DOI: 10.3389/fonc.2024.1409132.

References

Bridgewater J, Galle P, Khan S, Llovet J, Park J, Patel T . Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-89. DOI: 10.1016/j.jhep.2014.01.021. View

Versteijne E, van Dam J, Suker M, Janssen Q, Groothuis K, Akkermans-Vogelaar J . Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022; 40(11):1220-1230. DOI: 10.1200/JCO.21.02233. View

Toyoda M, Ajiki T, Fujiwara Y, Nagano H, Kobayashi S, Sakai D . Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). Cancer Chemother Pharmacol. 2014; 73(6):1295-301. PMC: 4032637. DOI: 10.1007/s00280-014-2431-y. View

Valle J, Lamarca A, Goyal L, Barriuso J, Zhu A . New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017; 7(9):943-962. PMC: 5586506. DOI: 10.1158/2159-8290.CD-17-0245. View

Rizzo A, Brandi G . Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treat Res Commun. 2021; 27:100334. DOI: 10.1016/j.ctarc.2021.100334. View

Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T . Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023; 401(10372):195-203. DOI: 10.1016/S0140-6736(22)02038-4. View

Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H . Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95(8):1685-95. DOI: 10.1002/cncr.10831. View

Shindo Y, Nagano H, Kanai M, Kobayashi S, Wada H, Sakai D . Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study. Oncol Rep. 2023; 49(2). PMC: 9868686. DOI: 10.3892/or.2023.8478. View

Yanagimoto H, Toyokawa H, Sakai D, Wada H, Satoi S, Yamamoto T . A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202). Cancer Chemother Pharmacol. 2018; 81(3):461-468. DOI: 10.1007/s00280-017-3513-4. View

10.

Woo S, Yoon K, Hong E, Park W, Han S, Park S . DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. Oncotarget. 2017; 8(46):81394-81404. PMC: 5655294. DOI: 10.18632/oncotarget.19037. View

11.

Fujiwara Y, Kobayashi S, Nagano H, Kanai M, Hatano E, Toyoda M . Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). PLoS One. 2015; 10(12):e0143072. PMC: 4669083. DOI: 10.1371/journal.pone.0143072. View

12.

Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M . Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008; 15(1):41-54. PMC: 2794356. DOI: 10.1007/s00534-007-1279-5. View

13.

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

14.

Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M . Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018; 105(3):192-202. DOI: 10.1002/bjs.10776. View

15.

Siebenhuner A, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J . Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer. 2018; 18(1):72. PMC: 5765636. DOI: 10.1186/s12885-017-3967-0. View

16.

Ishihara S, Horiguchi A, Endo I, Wakaki T, Hirano S, Yamaue H . Prognostic impact of the number of metastatic lymph nodes in distal bile duct cancer: An analysis of Japanese registration cases by the study group for biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2020; 27(7):396-401. DOI: 10.1002/jhbp.730. View

17.

Nakahashi K, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J . How long should follow-up be continued after R0 resection of perihilar cholangiocarcinoma?. Surgery. 2020; 168(4):617-624. DOI: 10.1016/j.surg.2020.04.068. View

18.

Shroff R, Kennedy E, Bachini M, Bekaii-Saab T, Crane C, Edeline J . Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019; 37(12):1015-1027. DOI: 10.1200/JCO.18.02178. View

19.

Kobayashi S, Nagano H, Sakai D, Eguchi H, Hatano E, Kanai M . Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol. 2014; 74(4):699-709. DOI: 10.1007/s00280-014-2543-4. View

20.

Fairweather M, Balachandran V, DAngelica M . Surgical management of biliary tract cancers. Chin Clin Oncol. 2016; 5(5):63. DOI: 10.21037/cco.2016.10.03. View